• Patients will often be able to notice appetite changes within a short period. Weight loss will be visible within a period of one to two months, and progress will be made as doses are adjusted.

  • Semaglutide and Tirzepatide regulate appetite hormones that control hunger and fullness. These GLP-1–based medications help reduce cravings, improve portion control, stabilize blood sugar, and support consistent, medically supervised weight loss over time.

  • Adults who are overweight or living with obesity, especially those who have struggled with diet and exercise alone, may be good candidates. Eligibility is determined through a medical evaluation that considers BMI, health history, metabolic factors, and weight loss goals.

  • Styku is completely non-invasive and uses harmless infrared light, making it safe for most individuals. It requires no radiation, contact, or discomfort. If you’re unsure about suitability due to medical conditions, our clinicians will evaluate your needs before scanning.

  • Yes. Styku evaluates waist circumference and waist-to-height ratio, two key indicators linked to metabolic and obesity-related risks. This helps identify early warning signs and allows Ellory Health to recommend personalized lifestyle changes, prevention strategies, and measurable inch-loss goals.

  • Most patients scan every four to six weeks for clear progress tracking. This timing reveals noticeable changes in fat loss, muscle tone, and body shape, helping your clinician adjust your treatment plan and giving you strong visual motivation to stay consistent.

  • Styku uses infrared technology to capture hundreds of measurements within seconds, offering over 99 percent measurement accuracy. This precision allows you and your clinician to monitor subtle changes, compare scans over time, and adjust your weight loss or fitness plan confidently.

  • The Styku 3D body scanner measures your body’s shape, circumference, posture, lean mass, and fat distribution with high accuracy. It creates a full 3D model so you can track inch-loss, identify risk areas, and see meaningful changes that may not show on the scale.

  • Tirzepatide is a prescription-only, once-weekly injectable medication that may be included in clinician-led weight management programs following a medical evaluation. It was originally developed for the treatment of type 2 diabetes and acts on two incretin receptors: GIP and GLP-1. In appropriate patients, it may be considered as part of a broader, medically supervised approach

  • This injectable medication is used as part of a clinician-led approach to weight management for adults with obesity or excess weight. It is prescribed following a medical evaluation and used alongside broader care considerations determined by a qualified healthcare provider. The treatment works through physiological pathways related to appetite and metabolism and is intended to